EZ-editor™ technology (CRISPR based), developed by Ubigene, is more efficient than general
CRISPR/Cas9 technology in double-strand breaking and homologous recombination. With EZ-editor™, Ubigene has
successfully edited over 10000 genes on more than 500 types of cell lines.
Objective
To create a Human TOMM6 Knockout
model in cell line by EZ-editor™-mediated genome engineering.
According to the Red Cotton database: the CRISPR gene-editing strategy design is Unknown. Knockout project comprehensive difficulty is thus assessed as Unknown.
Red Cotton™ Notes
Gene
TOMM6
had been KO in hek293t cell line.
EZ-editor™ Gene Dependency
EZ-editor™ Gene Expression Level
EZ-editor™ Gene Copy Number
EZ-editor™ Gene Dependency
Result
The TOMM6 gene you inquire is evaluated as high risk
in 2%
cell line.
Cell line is not selected, unable to assess the accurate risk level, for reference only.
In all cell lines, there is
99.4% cells with medium expression level,
0.6% cells with high expression level
of TOMM6 gene.
Cell line is not selected, unable to assess the accurate expression level, for reference only.
In all cell lines, there is
58.1% cells with low copy number,
36.9% cells with medium copy number,
4.9% cells with high copy number
of TOMM6 gene.
Cell line is not selected, unable to assess the accurate copy number, for reference only.
Ubigene is an international high-technology enterprise focused on gene-editing cells. Our exclusive EZ-editor™ technology has 10-20 times more efficient editing than traditional methods, easily achieving gene knockout, point mutation, and knock-in. Based on EZ-editor™ technology, Ubigene has accumulated over 6000 successful gene-editing cases from more than 300 cell lines including iPSC and ESC, and has established a KO Cell Line Bank with 5000+ KO cell lines and Red Cotton™ gRNA Plasmid Bank with 10000+ gRNA plasmids available in stock.
Ubigene focuses on technological innovation and product development, of which EZ-editor™ series products that cover the whole workflow of gene-editing keep improving. Ubigene will move on toward our goal of "Make genome editing easier" and we won't stop!